AdvisorShares Investments LLC Takes Position in Grifols, S.A. $GRFS

AdvisorShares Investments LLC purchased a new position in shares of Grifols, S.A. (NASDAQ:GRFS) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 101,600 shares of the biotechnology company’s stock, valued at approximately $1,012,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Brandes Investment Partners LP lifted its stake in shares of Grifols by 8.9% during the second quarter. Brandes Investment Partners LP now owns 28,035,461 shares of the biotechnology company’s stock worth $253,441,000 after purchasing an additional 2,294,113 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Grifols by 1.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 4,212,032 shares of the biotechnology company’s stock valued at $29,948,000 after purchasing an additional 80,507 shares in the last quarter. Bank of America Corp DE raised its stake in Grifols by 52.1% during the second quarter. Bank of America Corp DE now owns 3,017,675 shares of the biotechnology company’s stock valued at $27,280,000 after buying an additional 1,034,229 shares in the last quarter. New York State Common Retirement Fund lifted its stake in Grifols by 5.6% during the third quarter. New York State Common Retirement Fund now owns 2,589,406 shares of the biotechnology company’s stock worth $25,790,000 after purchasing an additional 136,678 shares during the last quarter. Finally, Sei Investments Co. lifted its position in shares of Grifols by 11.6% in the 2nd quarter. Sei Investments Co. now owns 2,081,535 shares of the biotechnology company’s stock worth $18,817,000 after buying an additional 216,793 shares during the last quarter.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. Weiss Ratings reissued a “hold (c)” rating on shares of Grifols in a report on Thursday, January 22nd. Zacks Research cut shares of Grifols from a “hold” rating to a “strong sell” rating in a report on Friday, December 5th. Wall Street Zen raised Grifols from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 15th. Finally, JPMorgan Chase & Co. dropped their price target on Grifols from $10.30 to $10.00 and set a “neutral” rating on the stock in a report on Monday, December 8th. One equities research analyst has rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $10.00.

Grifols Price Performance

NASDAQ GRFS opened at $9.28 on Friday. The company has a fifty day simple moving average of $9.10 and a 200 day simple moving average of $9.47. Grifols, S.A. has a 1 year low of $6.19 and a 1 year high of $11.14. The company has a quick ratio of 0.93, a current ratio of 2.48 and a debt-to-equity ratio of 1.20.

Grifols Company Profile

Grifols, Inc (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units.